公开(公告)号：US20210277111A1

公开(公告)日：2021-09-09

申请号：US17127324

申请日：2020-12-18

Applicant: Biogen MA Inc.

Inventor： Diego Cadavid ,  Sha Mi

IPC: C07K16/28 ,  A61K38/21 ,  A61K39/395 ,  A61K45/06

Abstract: Methods, compositions and kits are described herein useful for detecting and/or treating a CNS demyelinating disease.

公开(公告)号：US20200276303A1

公开(公告)日：2020-09-03

申请号：US16708695

申请日：2019-12-10

Applicant: Biogen MA Inc.

Inventor： Diego Cadavid ,  Sha Mi

IPC: A61K39/395 ,  C07K16/28 ,  A61B3/00 ,  A61B5/11 ,  A61B5/00 ,  A61K31/56 ,  A61K38/21 ,  G01R33/48

Abstract: Methods and compositions for enhancing one or more of: myelination, re-myelination, oligodendrocyte numbers, or neuroaxonal protection, while ameliorating an inflammatory condition in a human subject are disclosed. In certain embodiments, the methods and compositions described herein include a reparative agent (e.g., a LINGO-1 antagonist) and an immunomodulatory agent, in combination. Thus, methods, compositions and kits described herein can be useful for treating a CNS demyelinating disease.

公开(公告)号：US20200038385A1

公开(公告)日：2020-02-06

申请号：US16542746

申请日：2019-08-16

Applicant: BIOGEN MA INC.

Inventor： Jermaine Thomas ,  Sha Mi ,  Edward Yin-Shiang Lin ,  Guo Zhu Zheng ,  Bin Ma ,  Richard D. Caldwell ,  Kevin Guckian ,  Gnanasambandam Kumaravel

IPC: A61K31/445 ,  C07K16/28 ,  A61K39/395 ,  A61K38/21 ,  A61K31/695 ,  A61K31/55 ,  A61K31/517 ,  A61K31/498 ,  A61K31/4709 ,  A61K31/4545 ,  A61K31/225 ,  C07D215/20 ,  C07D401/06 ,  C07D405/12 ,  C07D211/62 ,  C07D211/60 ,  C07D211/34

Abstract: Compounds of formula (I) or (II) can modulate the activity of S1P receptors.

公开(公告)号：US20190060398A1

公开(公告)日：2019-02-28

申请号：US15918044

申请日：2018-03-12

Applicant: Biogen MA Inc.

Inventor： Sha Mi ,  R. Blake Pepinsky ,  John McCoy

IPC: A61K38/17 ,  C07K16/18 ,  A61K39/395 ,  C07K14/47 ,  C07K14/705 ,  A61K31/70 ,  C12N5/079 ,  A61K38/00 ,  A61K48/00

Abstract: The invention provides methods of treating diseases, disorders or injuries involving demyelination and dysmyelination, including multiple sclerosis, by the administration of a LINGO-4 antagonist.

公开(公告)号：US20160213745A1

公开(公告)日：2016-07-28

申请号：US14978289

申请日：2015-12-22

Applicant: Biogen MA Inc.

Inventor： Sha Mi ,  R. Blake Pepinsky ,  John McCoy

IPC: A61K38/17 ,  C07K16/18 ,  C07K14/47 ,  A61K39/395

CPC classification number: A61K38/1709 ,  A61K31/70 ,  A61K38/00 ,  A61K39/3955 ,  A61K48/00 ,  C07K14/47 ,  C07K14/70503 ,  C07K16/18 ,  C07K2317/76 ,  C07K2319/30 ,  C12N5/0622 ,  C12N2501/998 ,  C12N2502/08 ,  Y02A50/406

Abstract: The invention provides methods of treating diseases, disorders or injuries involving demyelination and dysmyelination, including multiple sclerosis, by the administration of a LINGO-4 antagonist.

Abstract translation: 本发明提供了通过施用LINGO-4拮抗剂治疗涉及脱髓鞘和脱髓鞘疾病（包括多发性硬化）的疾病，病症或损伤的方法。

公开(公告)号：US20200317775A1

公开(公告)日：2020-10-08

申请号：US16789738

申请日：2020-02-13

Applicant: Biogen MA Inc.

Inventor： Sha Mi ,  R. Blake Pepinsky ,  Zhaohui Shao ,  Ellen A. Garber Stark ,  Steven D. Miklasz ,  Christilyn Graff

IPC: C07K16/28

Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.

公开(公告)号：US10435467B2

公开(公告)日：2019-10-08

申请号：US15541944

申请日：2016-01-08

Applicant: Biogen MA Inc.

Inventor： Diego Cadavid ,  Sha Mi

IPC: A61K38/00 ,  C07K16/28 ,  A61K38/21 ,  A61K39/395 ,  A61K45/06 ,  C07K14/705 ,  A61K39/00

Abstract: Methods, compositions and kits comprising an anti-LINGO antibody molecule are described herein useful for detecting and/or treating a CNS demyelinating disease.

公开(公告)号：US20190161546A1

公开(公告)日：2019-05-30

申请号：US16018819

申请日：2018-06-26

Applicant: Biogen MA Inc.

Inventor： Sha Mi ,  R. Blake Pepinsky ,  Zhaohui Shao ,  Ellen A. Garber Stark ,  Steven D. Miklasz ,  Christilyn Graff

IPC: C07K16/28

Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.

公开(公告)号：US20180028511A1

公开(公告)日：2018-02-01

申请号：US15644352

申请日：2017-07-07

Applicant: BIOGEN MA INC.

Inventor： Jermaine Thomas ,  Sha Mi ,  Edward Yin-Shiang Lin ,  Guo Zhu Zheng ,  Bin Ma ,  Richard D. Caldwell ,  Kevin M. Guckian ,  Gnanasambandam Kumaravel

IPC: A61K31/445 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/498 ,  C07K16/28 ,  A61K31/55 ,  A61K31/695 ,  A61K38/21 ,  A61K39/395 ,  A61K31/225 ,  C07D215/20 ,  C07D405/12 ,  C07D401/06 ,  C07D211/62 ,  C07D211/60 ,  A61K31/517 ,  C07D211/34

CPC classification number: A61K31/445 ,  A61K31/225 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/498 ,  A61K31/517 ,  A61K31/55 ,  A61K31/695 ,  A61K38/21 ,  A61K39/3955 ,  C07D211/34 ,  C07D211/60 ,  C07D211/62 ,  C07D215/20 ,  C07D401/06 ,  C07D405/12 ,  C07K16/2842

Abstract: Compounds of formula (I) or (II) can modulate the activity of S1P receptors.

公开(公告)号：US09745375B2

公开(公告)日：2017-08-29

申请号：US15165279

申请日：2016-05-26

Applicant: Biogen MA Inc.

Inventor： Sha Mi ,  R. Blake Pepinsky ,  Christilyn Graff

IPC: C07K16/18 ,  A61K39/395 ,  C07K16/28 ,  A61K45/06 ,  A61K47/48 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/60 ,  A61K47/6849 ,  A61K47/6879 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/28 ,  C07K2317/21 ,  C07K2317/35 ,  C07K2317/41 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/01

Abstract: Endogenous LINGO-1 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous LINGO-1 function, such anti-LINGO-1 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for LINGO-1, and methods of using such antibodies as antagonists of endogenous LINGO-1 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-LINGO-1 antibody.